02 March 2019 (online)
We would like to thank Mr. Bohan for his comment as well as acknowledge the significance of the Bolton Relay device with Plus Delivery System.
As mentioned, the device has been demonstrated safe for utilization both with penetrating atherosclerotic ulcers (PAU) and descending thoracic aortic aneurysms (TAA) in the Bolton Relay Thoracic Aortic Endovascular Pivotal Trial demonstrating 5-year freedom from all-cause mortality as high as 57% compared with 50.2% (p = 0.289) in the surgical arm. With the improved Plus Delivery System, the Bolton Relay device is a considerable option for endovascular management of both TAAs and PAUs and may be considered for additional aortic pathologies as well. As with all current endovascular devices, long-term efficacy remains to be demonstrated and continued research will help to elucidate the longevity of endovascular interventions. Thank you.